Ultravate® 0.05% ointment, single exposure

DRUG2 trials

Sponsors

Actavis Inc.

Conditions

Healthy

Phase 1

The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

CompletedNCT00865267

Actavis Inc.Healthy

Start: 2003-12-31End: 2003-12-31Updated: 2010-08-17

Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

CompletedNCT00865605

Actavis Inc.Healthy

Start: 2003-12-31End: 2004-07-31Updated: 2010-08-17